Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score.

Pub Date : 2022-01-01 Epub Date: 2022-10-24 DOI:10.5114/wo.2022.120592
Heba F Taha, Dalia Hamouda Elsayed, Reham Salem, Doaa Mandour, Mohammed Bayomy, Hayam Rashed, Mostafa Kamel, Mohamed Elderey, Ola M Elfarargy
{"title":"Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score.","authors":"Heba F Taha, Dalia Hamouda Elsayed, Reham Salem, Doaa Mandour, Mohammed Bayomy, Hayam Rashed, Mostafa Kamel, Mohamed Elderey, Ola M Elfarargy","doi":"10.5114/wo.2022.120592","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We aimed to evaluate the outcome of treatment with docetaxel plus androgen deprivation therapy (ADT) in newly diagnosed patients with metastatic high tumor burden hormone-sensitive prostate cancer (mHSPC) and correlated the outcome with hemoglobin, albumin, lymphocyte and platelets (HALP) score.</p><p><strong>Material and methods: </strong>Six cycles of docetaxel plus ADT were given to 50 patients with high burden mHSPC. Baseline HALP score was calculated and disease outcome was tabulated; moreover, the prognostic impact of the HALP score in response to treatment and survival was calculated.</p><p><strong>Results: </strong>We found a significant association between high HALP score and response to treatment where a higher rate of complete response occurred in patients with a high HALP score than in patients with a low HALP score (53.8% vs. 5.4% respectively, <i>p</i>-value = 0.001). Patients with ≥ 12-month-duration castration-resistant prostate cancer (CRPC) had a significantly higher HALP score compared to patients with a lower HALP score (84.6% vs. 35.1% respectively, <i>p</i>-value = 0.002); 18-month-duration CRPC-free survival was significantly greater in patients with higher HALP score than patients with a lower HALP score (23.1% and 5.4% respectively, <i>p</i>-value < 0.001). Patients with a high HALP score had insignificantly higher mean overall survival than patients with a low HALP score (mean: 22.91 and 20.66 months respectively, <i>p</i>-value = 0.230).</p><p><strong>Conclusions: </strong>Our results confirmed the benefits of treatment with docetaxel plus ADT in high-burden mHSPC with accepted tolerance. HALP score was found to be an independent predictive factor for benefit from therapy; we can apply it as an easy way to stratify patients for appropriate selection of treatment for better tolerance and outcome.</p>","PeriodicalId":72699,"journal":{"name":"","volume":"26 3","pages":"196-203"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/48/WO-26-48040.PMC9641632.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/wo.2022.120592","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: We aimed to evaluate the outcome of treatment with docetaxel plus androgen deprivation therapy (ADT) in newly diagnosed patients with metastatic high tumor burden hormone-sensitive prostate cancer (mHSPC) and correlated the outcome with hemoglobin, albumin, lymphocyte and platelets (HALP) score.

Material and methods: Six cycles of docetaxel plus ADT were given to 50 patients with high burden mHSPC. Baseline HALP score was calculated and disease outcome was tabulated; moreover, the prognostic impact of the HALP score in response to treatment and survival was calculated.

Results: We found a significant association between high HALP score and response to treatment where a higher rate of complete response occurred in patients with a high HALP score than in patients with a low HALP score (53.8% vs. 5.4% respectively, p-value = 0.001). Patients with ≥ 12-month-duration castration-resistant prostate cancer (CRPC) had a significantly higher HALP score compared to patients with a lower HALP score (84.6% vs. 35.1% respectively, p-value = 0.002); 18-month-duration CRPC-free survival was significantly greater in patients with higher HALP score than patients with a lower HALP score (23.1% and 5.4% respectively, p-value < 0.001). Patients with a high HALP score had insignificantly higher mean overall survival than patients with a low HALP score (mean: 22.91 and 20.66 months respectively, p-value = 0.230).

Conclusions: Our results confirmed the benefits of treatment with docetaxel plus ADT in high-burden mHSPC with accepted tolerance. HALP score was found to be an independent predictive factor for benefit from therapy; we can apply it as an easy way to stratify patients for appropriate selection of treatment for better tolerance and outcome.

Abstract Image

Abstract Image

多西他赛治疗转移性激素敏感性前列腺癌的疗效以及与血红蛋白、白蛋白、淋巴细胞和血小板评分的相关性。
简介我们旨在评估多西他赛联合雄激素剥夺疗法(ADT)对新诊断的转移性高肿瘤负荷激素敏感性前列腺癌(mHSPC)患者的治疗效果,并将治疗效果与血红蛋白、白蛋白、淋巴细胞和血小板(HALP)评分相关联:材料: 50 名高负荷 mHSPC 患者接受了 6 个周期的多西他赛加 ADT 治疗。此外,还计算了HALP评分对治疗反应和生存期的预后影响:结果:我们发现 HALP 高分与治疗反应之间存在明显关联,HALP 高分患者的完全反应率高于 HALP 低分患者(分别为 53.8% 对 5.4%,P 值 = 0.001)。病程≥12个月的阉割耐药前列腺癌(CRPC)患者的HALP评分明显高于HALP评分较低的患者(分别为84.6%和35.1%,P值=0.002);HALP评分较高的患者的18个月无CRPC生存率明显高于HALP评分较低的患者(分别为23.1%和5.4%,P值<0.001)。HALP评分高的患者的平均总生存期明显高于HALP评分低的患者(分别为22.91个月和20.66个月,P值=0.230):我们的研究结果证实,多西他赛联合ADT治疗高负担、可耐受的mHSPC患者有一定疗效。我们发现,HALP评分是治疗获益的一个独立预测因素;我们可以将其作为一种简便的方法,对患者进行分层,以便适当选择治疗方法,从而获得更好的耐受性和疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信